Saturday 17 October 2026
Export STRO’s income statement to Excel — free account
Sutro Biopharma, Inc.
STRO Healthcare Biotechnology
Sutro Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $102.5 million, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue fell 84.6%, EPS fell 66.4% and free cash flow grew 14.6%, each against the same quarter a year earlier.
10.87
0.59
−5.15%
Follow STRO
Sutro Biopharma, Inc. (STRO) P/E ratio
Sutro Biopharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.6× (June 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.6×
Ten-year median
0.0×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRDA Entrada Therapeutics, Inc. compare | n/m |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| UPB Upstream Bio, Inc. compare | n/m |
| ACOG Alpha Cognition Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| YARW Yarrow Bioscience, Inc compare | n/m |
| STRO Sutro Biopharma, Inc. | n/m |
| CGEN Compugen Ltd. compare | 5.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)